12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PEG-SN38: Phase I started

Enzon began an open-label Phase I trial to evaluate 9 mg/m 2 IV EZN-2208 given on days 1, 8 and 15 of a 28-day cycle in combination with biweekly...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >